Using an improvement model to reduce adverse drug events in VA facilities.

BACKGROUND Adverse drug events cause significant morbidity and mortality in health care. Many adverse drug events are due to medication errors and are preventable. In 1999 and 2000 the Patient Safety Center of Inquiry collaborated with the Institute for Healthcare Improvement (IHI) to implement a quality improvement (QI) project designed to reduce medication errors within the Veterans Administration system. METHODS During a 6- to 9-month period, interdisciplinary teams that want to achieve much higher levels of performance work on a common aim, under the guidance of faculty, and come together for three 2-day educational and planning sessions. Between these sessions, teams implement some of the suggested changes, measure the results of those changes, and report back to the larger group. RESULTS During the formal project, teams collected allergy information on more than 20,000 veterans and averted 1,833 medication errors that had the potential to cause adverse events. At 6-month follow-up, the majority of teams remained intact, continued to collect data, and maintained their gains, approximately doubling the results obtained during the formal project. Half of the teams expanded their efforts to other settings, and one-third of the teams expanded beyond their original topics. Returns on investment in the QI effort were substantial. CONCLUSIONS The results suggest that gains made in organized QI efforts can be maintained for 6 months without additional external support or coaching if team structure and leadership support remain intact. Facilitators of QI efforts should focus on teams that are having difficulty learning new techniques. Finally, this effort appeared to generate cost savings.

[1]  N. Laird,et al.  Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .

[2]  L. Baker,et al.  Managed care and technology diffusion: the case of MRI. , 1998, Health affairs.

[3]  H Pohl,et al.  Medication prescribing errors in a teaching hospital. , 1990, JAMA.

[4]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[5]  D. Bates,et al.  Systems analysis of adverse drug events. ADE Prevention Study Group. , 1995, JAMA.

[6]  S. Crystal,et al.  The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. , 1995, Health services research.

[7]  J. Coleman,et al.  Medical Innovation: A Diffusion Study. , 1967 .

[8]  T W Nolan,et al.  Reducing adverse drug events: lessons from a breakthrough series collaborative. , 2000, The Joint Commission journal on quality improvement.

[9]  E. Steinberg,et al.  X-ray CT and magnetic resonance imagers. Diffusion patterns and policy issues. , 1985, The New England journal of medicine.

[10]  L. Dintenfass HONESTY IN CONFUSION. , 1965, Lancet.

[11]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[12]  A. Kasumi,et al.  The Spread of Upper Gastrointestinal Endoscopy in Japan and the United States: An International Comparative Analysis of Technology Diffusion , 1993, International Journal of Technology Assessment in Health Care.

[13]  R. Busse,et al.  CARDIAC CATHETERIZATION IN GERMANY , 1999, International Journal of Technology Assessment in Health Care.

[14]  J C Russo,et al.  Medication error prevention by clinical pharmacists in two children's hospitals. , 1987, Pediatrics.

[15]  D. Menon,et al.  Diffusion of Laparoscopic Cholecystectomy in Canada , 1994, International Journal of Technology Assessment in Health Care.

[16]  Lucian L. Leape,et al.  Reducing adverse drug events , 1998 .

[17]  M. Nichter,et al.  Changing patterns of pharmaceutical practice in the United States. , 1997, Social science & medicine.

[18]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[19]  R. Shepherd,et al.  The challenge of disseminating new medical technologies: treatment of cardiac arrhythmias. , 1990, QRB. Quality review bulletin.

[20]  TonseN. K. Raju,et al.  MEDICATION ERRORS IN NEONATAL AND PAEDIATRIC INTENSIVE-CARE UNITS , 1989, The Lancet.

[21]  A. D. Spiegel,et al.  Risk Management in Health Care Institutions: A Strategic Approach , 1997 .

[22]  Schwartz Js,et al.  The adoption and diffusion of CT and MRI in the United States. A comparative analysis. , 1985 .

[23]  J A Shea,et al.  Diffusion of Laparoscopic Cholecystectomy Among General Surgeons in the United States , 1995, Medical care.

[24]  T. Brennan,et al.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.

[25]  D S Stein,et al.  Factors related to errors in medication prescribing. , 1997, JAMA.

[26]  K. Levit,et al.  Health spending in 1998: signals of change. The Health Accounts Team. , 2018, Health affairs.

[27]  W. W. Young,et al.  Dissemination of clinical results. Mastectomy versus lumpectomy and radiation therapy. , 1996, Medical care.

[28]  B. Kirkman-Liff,et al.  The hepatitis B vaccine: utilization decision process and outcomes in community hospitals. , 1985, Health services research.

[29]  A. Fendrick,et al.  Hospital adoption of laparoscopic cholecystectomy. , 1994, Medical care.

[30]  James T. Reason,et al.  Managing the risks of organizational accidents , 1997 .

[31]  E. G. Elinsky,et al.  Magnetic Resonance Imaging: Diffusion of Technology in an Ambulatory Setting , 1992, International Journal of Technology Assessment in Health Care.

[32]  M. Pollard Pharmaceutical Innovation in the United States: Factors Affecting Future Performance , 1993, International Journal of Technology Assessment in Health Care.